Biogen Forecast, price target & analysts
Biogen Target price 2025 - Analyst rating & recommendation
Biogen Classifications & Recommendation:
Biogen Price Target
| Target Price | $155.04 |
| Price | $142.50 |
| Potential | 8.80% |
| Number of Estimates | 32 |
| 32 Analysts have issued a price target Biogen 2026 . The average Biogen target price is $155.04. This is 8.80% higher than the current stock price. The highest price target is $273.00 91.58% , the lowest is $119.18 16.36% . | |
| A rating was issued by 42 analysts: 21 Analysts recommend Biogen to buy, 20 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Biogen stock has an average upside potential 2026 of 8.80% . Most analysts recommend the Biogen stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
37 Analysts have issued a sales forecast Biogen 2025 . The average Biogen sales estimate is $9.9b . This is 1.28% lower than the revenue of the last 12 months(TTM). The highest sales forecast is $10.5b 5.34% , the lowest is $9.3b 6.73% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $9.7b | 1.62% |
|---|---|---|
| 2025 | $9.9b | 2.00% |
| 2026 | $9.5b | 4.03% |
| 2027 | $9.5b | 0.24% |
| 2028 | $9.7b | 1.76% |
| 2029 | $9.7b | 0.06% |
| 2030 | $9.6b | 0.96% |
| 2031 | $9.4b | 1.80% |
| 2032 | $9.4b | 0.37% |
17 Analysts have issued an Biogen EBITDA forecast 2025. The average Biogen EBITDA estimate is $3.4b . This is 5.28% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $4.0b 23.88% , the lowest is $3.0b 7.18% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $3.0b | 25.80% |
|---|---|---|
| 2025 | $3.4b | 10.70% |
| 2026 | $3.5b | 3.18% |
| 2027 | $3.5b | 0.84% |
| 2028 | $3.9b | 11.69% |
| 2029 | $4.0b | 2.25% |
| 2030 | $4.0b | 0.80% |
| 2031 | $5.6b | 40.79% |
| 2032 | $6.1b | 9.78% |
EBITDA Margin
| 2024 | 31.40% | 27.87% |
|---|---|---|
| 2025 | 34.08% | 8.55% |
| 2026 | 36.64% | 7.51% |
| 2027 | 36.85% | 0.57% |
| 2028 | 40.45% | 9.77% |
| 2029 | 41.34% | 2.20% |
| 2030 | 41.40% | 0.15% |
| 2031 | 59.36% | 43.38% |
| 2032 | 64.93% | 9.38% |
38 Biogen Analysts have issued a net profit forecast 2025. The average Biogen net profit estimate is $2.4b . This is 55.07% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $2.5b 62.75% , the lowest is $2.2b 45.59% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $1.6b | 40.57% |
|---|---|---|
| 2025 | $2.4b | 45.41% |
| 2026 | $2.4b | 0.44% |
| 2027 | $2.5b | 3.98% |
| 2028 | $2.6b | 4.42% |
| 2029 | $2.6b | 0.18% |
| 2030 | $2.5b | 4.53% |
| 2031 | $2.5b | 0.96% |
| 2032 | $2.5b | 2.88% |
Net Margin
| 2024 | 16.87% | 42.89% |
|---|---|---|
| 2025 | 24.05% | 42.57% |
| 2026 | 24.95% | 3.74% |
| 2027 | 25.88% | 3.73% |
| 2028 | 26.55% | 2.59% |
| 2029 | 26.58% | 0.11% |
| 2030 | 25.63% | 3.57% |
| 2031 | 26.35% | 2.81% |
| 2032 | 27.01% | 2.50% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
38 Analysts have issued a Biogen forecast for earnings per share. The average Biogen EPS is $16.19 . This is 55.23% higher than earnings per share in the financial year 2024. The highest EPS forecast is $16.99 62.90% , the lowest is $15.20 45.73% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $11.19 | 40.40% |
|---|---|---|
| 2025 | $16.19 | 44.68% |
| 2026 | $16.12 | 0.43% |
| 2027 | $16.76 | 3.97% |
| 2028 | $17.50 | 4.42% |
| 2029 | $17.53 | 0.17% |
| 2030 | $16.74 | 4.51% |
| 2031 | $16.90 | 0.96% |
| 2032 | $17.38 | 2.84% |
P/E ratio
| Current | 13.66 | 44.55% |
|---|---|---|
| 2025 | 8.80 | 35.59% |
| 2026 | 8.84 | 0.45% |
| 2027 | 8.50 | 3.85% |
| 2028 | 8.14 | 4.24% |
| 2029 | 8.13 | 0.12% |
| 2030 | 8.51 | 4.67% |
| 2031 | 8.43 | 0.94% |
| 2032 | 8.20 | 2.73% |
Based on analysts' sales estimates for 2025, the Biogen stock is valued at an EV/Sales of 2.47 and an P/S ratio of 2.12 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 2.44 | 28.24% |
|---|---|---|
| 2025 | 2.47 | 1.40% |
| 2026 | 2.58 | 4.20% |
| 2027 | 2.57 | 0.24% |
| 2028 | 2.53 | 1.73% |
| 2029 | 2.53 | 0.06% |
| 2030 | 2.55 | 0.97% |
| 2031 | 2.60 | 1.83% |
| 2032 | 2.59 | 0.37% |
P/S ratio
| Current | 2.09 | 29.06% |
|---|---|---|
| 2025 | 2.12 | 1.30% |
| 2026 | 2.21 | 4.20% |
| 2027 | 2.20 | 0.24% |
| 2028 | 2.16 | 1.73% |
| 2029 | 2.16 | 0.06% |
| 2030 | 2.18 | 0.97% |
| 2031 | 2.22 | 1.83% |
| 2032 | 2.21 | 0.37% |
Current Biogen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Hold
➜
Hold
|
Unchanged | Sep 04 2025 |
| Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Aug 14 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Aug 01 2025 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Aug 01 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 01 2025 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 01 2025 |
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Jun 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Needham:
Hold
➜
Hold
|
Sep 04 2025 |
|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Aug 14 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Aug 01 2025 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Aug 01 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Aug 01 2025 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 01 2025 |
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Jun 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
